Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors
暂无分享,去创建一个
Michael E. Phelps | Yann Seimbille | Harvey Herschman | Wolfgang Weber | Johannes Czernin | Steven Dubinett | M. Phelps | Y. Seimbille | J. Czernin | W. Weber | H. Herschman | S. Dubinett | H. Su | Rebecca A. Dumont | C. Bodenstein | Rebecca A Dumont | Helen Su | Claudia Bodenstein | R. Dumont
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[3] É. Hajduch,et al. Protein kinase B (PKB/Akt) – a key regulator of glucose transport? , 2001, FEBS letters.
[4] G. Giaccone,et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cells , 2006 .
[5] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[6] John Eric Wilson. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function , 2003, Journal of Experimental Biology.
[7] William Pao,et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[8] Patricia L. Harris,et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] G. Kéri,et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). , 2005, Cancer research.
[10] M. Forte,et al. Is there VDAC in cell compartments other than the mitochondria? , 1996, Journal of bioenergetics and biomembranes.
[11] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[12] Young Tae Kim,et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Michael E Phelps,et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] G. Giaccone,et al. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] M. Meyerson,et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. , 2005, Cancer research.
[16] G. Giaccone,et al. EGFR inhibitors: what have we learned from the treatment of lung cancer? , 2005, Nature Clinical Practice Oncology.
[17] P K Banerjee,et al. Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[19] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[20] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[21] S. Siegel,et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] A. Harris,et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] William Pao,et al. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Mills,et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.
[25] Wolfgang A Weber,et al. Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Otto S Hoekstra,et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Phelps,et al. Fluorine-18 labeling of 6,7-disubstituted anilinoquinazoline derivatives for positron emission tomography (PET) imaging of tyrosine kinase receptors: synthesis of 18F-Iressa and related molecular probes , 2005 .
[28] M. Schwaiger,et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Sanjiv Sam Gambhir,et al. AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.
[30] G. Kéri,et al. Multidrug Transporter ABCG 2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa ( ZD 1839 , Gefitinib ) , 2005 .
[31] Elisa Rossi,et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.
[32] J. Mendelsohn. Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Kusumoto,et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. , 2004, Lung cancer.
[35] Y H Xu,et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. , 1984, Science.
[36] Yusuke Nakamura,et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.
[37] M. Caplan,et al. Molecular requirements for the cell-surface expression of multisubunit ion-transporting ATPases. Identification of protein domains that participate in Na,K-ATPase and H,K-ATPase subunit assembly. , 1993, The Journal of biological chemistry.
[38] G. Giaccone,et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. , 2006, International journal of cancer.
[39] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[40] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[41] Zhong Wen-zhao,et al. Erlotinib in Lung Cancer - Molecular and Clinical Predictors of Outcome , 2006 .
[42] J. Minna,et al. Gefitinib and erlotinib sensitivity in a panel of non-small cell lung cancer (NSCLC) cell lines , 2005 .
[43] N. Hanna,et al. EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib , 2006 .
[44] David M. Thomas,et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. , 2005, Cancer research.
[45] N. Hanna. Erlotinib in-Previously Treated Non-Small-Cell Lung CancerShepherd FA (for the National Cancer Institute of Canada Clinical Trials Group Univ of Toronto; et al N Engl J Med 353:123-132, 2005§ , 2006 .
[46] W C Eckelman,et al. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. , 1999, Cancer research.
[47] G. Daley,et al. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation , 2005, Oncogene.
[48] C. Mermel,et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[49] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[50] R. Robey,et al. Thrombin is a novel regulator of hexokinase activity in mesangial cells. , 2000, Kidney international.
[51] Patrick L Chow,et al. A method of image registration for small animal, multi-modality imaging , 2006, Physics in medicine and biology.